| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | NEUTRAL | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 4.06▼ | 4.06▼ | 4.10▼ | 4.25▼ | 4.13▼ |
| MA10 | 4.13▼ | 4.14▼ | 4.17▼ | 4.10▼ | 3.17▲ |
| MA20 | 4.18▼ | 4.22▼ | 4.23▼ | 4.06▼ | 2.64▲ |
| MA50 | 4.22▼ | 4.21▼ | 4.11▼ | 3.23▲ | 2.16▲ |
| MA100 | 4.25▼ | 4.02▼ | 4.03▼ | 2.64▲ | 2.89▲ |
| MA200 | 4.06▼ | 4.24▼ | 3.85▲ | 2.17▲ | 4.09▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.026▼ | -0.035▼ | -0.048▼ | -0.042▼ | 0.202▲ |
| RSI | 31.495▼ | 37.041▼ | 38.946▼ | 51.633▲ | 65.193▲ |
| STOCH | 2.083▼ | 18.552▼ | 21.949 | 67.348 | 24.186 |
| WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -60.000 | -80.912▼ |
| CCI | -163.854▼ | -160.519▼ | -154.375▼ | 28.791 | 66.018 |
|
Wednesday, November 19, 2025 02:11 PM
An update from NervGen Pharma ( ($TSE:NGEN) ) is now available. NervGen Pharma has successfully closed a US$10 million non-brokered private ...
|
|
Wednesday, November 19, 2025 05:57 AM
In conjunction with the financing, Minerva will bring on additional board members with significant schizophrenia clinical trial experience, to further strengthen and support clinical operations and ...
|
|
Tuesday, November 18, 2025 02:12 PM
An announcement from NervGen Pharma ( ($TSE:NGEN) ) is now available. NervGen Pharma has announced a US$10 million non-brokered private placement ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 21/11/25 | 4.31 | 4.31 | 3.93 | 3.94 | 42,700 |
| 20/11/25 | 4.30 | 4.385 | 4.11 | 4.34 | 72,700 |
| 19/11/25 | 4.20 | 4.42 | 4.14 | 4.30 | 40,900 |
| 18/11/25 | 4.30 | 4.38 | 4.07 | 4.30 | 177,558 |
| 17/11/25 | 4.17 | 4.60 | 3.90 | 4.36 | 319,100 |
| 14/11/25 | 3.75 | 4.21 | 3.75 | 4.11 | 89,929 |
| 13/11/25 | 3.88 | 3.97 | 3.7818 | 3.85 | 78,728 |
| 12/11/25 | 3.91 | 4.20 | 3.90 | 4.00 | 70,100 |
| 11/11/25 | 3.85 | 4.05 | 3.76 | 3.97 | 73,600 |
| 10/11/25 | 3.78 | 3.862 | 3.63 | 3.81 | 52,100 |
|
|
||||
|
|
||||
|
|